Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Exp Hematol. 2009 May;37(5):533–538. doi: 10.1016/j.exphem.2009.02.001

Figure 1.

Figure 1

The selectivity of BAY 60-6583 as an A2bAR agonist. (A) Western blotting of VASP in WT peritoneal macrophages treated with BAY 60-6583 at 1 μM for 10 min after 30 min pre-incubation with the following antagonists, MRS1754 (10 μM) to A2bAR; CVT-6883 (1 μM) to A2bAR; DPCPX (1 μM) to A1AR, SCH442416 (1 μM) to A2aAR, and MRS1191 (1 μM) to A3AR. PKA phosphorylates VASP at serine 157 and as a result VASP shifts from 46 to 50 kDa in SDS-PAGE [24]. BAY 60-6583 was used at 1 μM following preliminary experiments with lower and higher concentrations. The membrane was also reacted with anti-β-actin as loading control. Shown is a representative blot from three experiments. (B) Western blotting of VASP in peritoneal macrophages from WT and A2bAR KO mice treated with BAY 60-6583 at different doses, as indicated. Shown is a representative blot from three experiments. (C) Western blotting of VASP in peritoneal macrophages from WT and A2bAR KO mice treated with 1 μM BAY 60-6583 for different times, as indicated.